ReviewGenes & diseases2026
Research progress in metabolic reprogramming and targeting metabolic pathways for clear cell renal cell carcinoma.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC), the most common pathological subtype of renal cancer, is characterized by distinctive metabolic reprogramming that serves as a core molecular pathological basis driving tumorigenesis, progression, and therapeutic resistance. The metabolic remodeling in ccRCC primarily manifests as dysregulated glucose metabolism, lipid accumulation, imbalanced amino acid utilization, and mitochondrial dysfunction. These alterations collectively sustain tumor cell bioenergetic demands, biosynthetic precursor supply, and redox homeostasis maintenance. Recent advances in multi-omics technologies and spatially resolved analytical methods have propelled ccRCC metabolism research beyond macroscopic description toward mechanistic investigation and targeted intervention. This article systematically reviews research progress focusing on metabolic reprogramming of ccRCC and the development of related therapeutic agents for this cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.